Your argument is somewhat contradictory, IMO. You contend that statins likely work via a mechanism other than LDL, but the hard evidence you say regulators should require for any hypothesis involving CV biomarkers is lacking for the posited alternative MoA.
Hence, I think LDL will continue to hold a privileged place among CV biomarkers based on the longstanding outcomes data for statins—until a truly compelling study comes along to alter this thinking. For a variety of reasons, IMPROVE-IT by itself does not have sufficient weight to effectuate a major change.
News 
Market Data 
Discover 
